Dacarbazine
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
Emcyt · ESTR
Hormonal–alkylating conjugate · approved 1981 · 7 citations
Largely superseded — displaced in prostate cancer by taxanes and androgen-receptor-pathway agents (abiraterone, enzalutamide, darolutamide); ~5 papers/year over the last five years. Its renal signal is hemodynamic (estrogenic fluid retention, venous thromboembolism), not direct nephrotoxicity.
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
An estradiol-mustard conjugate whose renal signal is hemodynamic — estrogenic fluid retention and thromboembolism, not direct nephrotoxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Renal injury is hemodynamic/prerenal rather than a quantified direct rate. The dominant safety liability is venous (and arterial/cardiovascular) thromboembolism with fluid retention/edema; in randomized data the majority of cardiovascular complications occurred within the first year.Source: Petrylak et al., NEJM 2004
Edema and VTE develop within weeks up to the first 2 months.
Distilled from: “Edema/VTE within weeks to the first 2 months.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Conjugate of estradiol and a nitrogen mustard (normustine) joined by a carbamate link. It acts mainly as an antimicrotubule agent — binding microtubule-associated proteins and beta-tubulin to disrupt the mitotic spindle (rather than primarily as an alkylator) — while the estradiol moiety suppresses gonadotropins and testosterone; it synergizes with taxanes.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Class-level context for the major non-renal toxicities of the Hormonal–alkylating conjugate class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 437 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
120 of 437 reports
Reported with hospitalization
156 of 437 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 82 of the 437 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Estramustine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
DTIC · Alkylator
Rare hepatic veno-occlusive disease; minimal direct renal injury.
Elspar · Enzyme
Rare AKI; pancreatitis-mediated.
Welireg · HIF-2α inhibitor
Anemia/hypoxia; emerging renal profile in VHL/RCC.
Halaven · Microtubule inhibitor
Reduced clearance in renal impairment.
Camptosar · Topoisomerase I inhibitor
Diarrhea-driven prerenal AKI.
Elahere · Antibody-drug conjugate (FRα/DM4)
Ocular toxicity dominates; renal involvement indirect/case-level (GI volume loss).
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.